RA Capital Funds, Directors Buy $8.76M in Mineralys Therapeutics Stock
MLYS has more than doubled off its 52-week low of $10.44 on elevated volume (2.0× avg).
Summary
RA Capital Healthcare Fund LP and affiliated entities, including directors Peter Kolchinsky and Rajeev Shah, made significant open market purchases of Mineralys Therapeutics common stock totaling $8.76 million.
Key Events · Ownership and Investor Activity · MLYS
-
Significant Insider Purchase
RA Capital Healthcare Fund LP and its affiliates, including directors Peter Kolchinsky and Rajeev Shah, acquired 369,000 shares of Mineralys Therapeutics common stock.
-
Substantial Investment Value
The open market purchases totaled $8,762,797, executed between March 27 and March 30, 2026, at prices ranging from $23.67 to $24.16 per share.
-
Institutional Confidence
This transaction by a major institutional investor with board representation indicates strong belief in the company's prospects, particularly following the recent FDA NDA acceptance for lorundrostat.
Analysis · MLYS · Life Sciences
This substantial open market purchase by RA Capital, a major institutional investor with board representation, signals strong conviction in Mineralys Therapeutics. The acquisition of nearly $8.8 million in shares, representing a notable percentage of the company's market capitalization, suggests that key insiders associated with the fund see significant value at current price levels. This comes after the company's recent 10-K filing confirmed FDA acceptance of its NDA for lorundrostat, with a PDUFA date set for December 2026, indicating confidence ahead of a critical regulatory milestone.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MLYS was trading at $28.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $10.44 to $47.65. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.